Your session is about to expire
Itraconazole vs Terbinafine
Introduction
For patients dealing with fungal infections, certain medications that inhibit the growth of fungi can help in managing symptoms and eliminating the infection. Itraconazole and Terbinafine are two such antifungal drugs often prescribed for conditions like ringworm, athlete's foot, or nail fungus. Both work by disrupting the cell membrane of fungi but affect different aspects of its synthesis. Itraconazole is a broad-spectrum triazole antifungal agent that works by inhibiting cytochrome P-450 dependent steps in the biosynthesis of ergosterol, a vital component of fungal cell membranes. On the other hand, Terbinafine is an allylamine antifungal drug that primarily interferes with ergosterol production by inhibiting squalene epoxidase, another key enzyme involved in this process.
Itraconazole vs Terbinafine Side By Side
| Attribute | Sporanox | Lamisil |
|---|---|---|
| Brand Name | Sporanox | Lamisil |
| Contraindications | Should not be taken with certain heart condition drugs due to potentially dangerous interactions. Requires monitoring of liver function. | Fewer reported interactions but requires caution especially with antidepressants and beta-blockers. Monitoring of liver function is advised. |
| Cost | For the generic version, approximately $1.40 to $4 per day depending on dosage. | For the generic version, prices range from roughly $.70 cents per day to nearly two dollars a day at higher doses. |
| Generic Name | Itraconazole | Terbinafine |
| Most Serious Side Effect | Significant liver damage, heart problems | Liver problems, changes in sense of taste or smell which could be permanent |
| Severe Drug Interactions | Can interact with a significant number of other drugs. | Generally has fewer drug interactions, but still requires caution. |
| Typical Dose | 200–400 mg/day | 250 mg/day |
What is Itraconazole?
Itraconazole (the generic name for Sporanox) is a part of the triazole group of antifungals, which marked a significant advancement from the earlier class known as imidazoles. Itraconazole was first approved by the FDA in 1992. It operates by preventing fungal cells from producing ergosterol, an essential component of their cell membrane - effectively "trapping" them without building blocks to grow and spread within your body over time. It is prescribed for treating various forms of fungal infections such as blastomycosis, histoplasmosis, and onychomycosis among others. Itraconazole has a selective influence on fungal cells with only minor effects on human cells resulting in it having fewer side effects than other antifungal drugs that have stronger impacts on these host cells.
On the other hand, Terbinafine (generic name for Lamisil), another widely used antifungal medication which was first approved by FDA in 1996, belongs to allylamines group and works slightly differently: it also inhibits ergosterol synthesis but at an earlier stage than azole-group antifungals like itraconazole do.
What conditions is Itraconazole approved to treat?
Itraconazole and Terbinafine are both approved for the treatment of various types of fungal infections:
- Itraconazole is often used to treat systemic fungal infections, such as blastomycosis, histoplasmosis, and aspergillosis. It can also be used for certain fungal infections in the nails.
- Terbinafine is primarily prescribed for treating onychomycosis (a nail fungus) caused by dermatophyte fungi, but it can also be effective against other types of skin-based fungal infections like ringworm or jock itch.
How does Itraconazole help with these illnesses?
Itraconazole is an antifungal medication used to treat a variety of fungal infections. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. By doing so, itraconazole disrupts the structure and function of these membranes which leads to leakage and ultimately causes death of the fungus.
Terbinafine also tackles fungal infections but in a slightly different way. It primarily inhibits squalene epoxidase, another enzyme involved in ergosterol synthesis. This action prevents the fungi from producing necessary compounds for their cell membrane thus causing them to die off.
Both drugs are effective against similar types of fungi but their differences lie more in side effects and drug interactions. Terbinafine tends not to interact with as many other medications as itraconazole does, however, both can cause liver toxicity so regular monitoring is needed during treatment.
What is Terbinafine?
Terbinafine, sold under the brand name Lamisil among others, is an antifungal medication used to treat a variety of fungal infections. It works by inhibiting a fungal enzyme called squalene epoxidase, which promotes the synthesis of ergosterol - an essential component of fungal cell membranes. This action disrupts cell membrane function and leads to fungal cell death.
Terbinafine was first approved by the FDA in 1996 and it's available over-the-counter or as a prescription drug in oral tablet form or topical cream, gel or spray for skin infections. Unlike Itraconazole which may interact with certain medications and has some contraindications including heart failure, Terbinafine generally has fewer drug interactions and can be tolerated better by patients with underlying cardiac conditions.
As an allylamine antifungal drug, it does not inhibit cytochrome P450 enzyme system like azole-type antifungals (including Itraconazole), meaning its metabolism isn't significantly impacted by other drugs metabolized via this pathway. Its side-effect profile also differs from that of azole-type drugs such as Itraconazole; common side effects include gastrointestinal upsets and rashes rather than potentially more serious cardiovascular events associated with long-term use of some azoles. The effectiveness of Terbinafine against dermatophyte fungi makes it particularly useful for treating nail fungus (onychomycosis) and athlete's foot (tinea pedis).
What conditions is Terbinafine approved to treat?
Terbinafine is a popular antifungal medication approved for the treatment of:
- Fungal infections of the fingernail and toenail (onychomycosis)
- Skin infections such as ringworm, jock itch, and athlete's foot.
Its effectiveness in treating these conditions has made it a go-to choice for many healthcare providers when tackling fungal issues.
How does Terbinafine help with these illnesses?
Terbinafine is an antifungal medication that inhibits the enzyme squalene epoxidase, which plays a crucial role in fungal cell wall synthesis. By blocking this enzyme, terbinafine causes a build-up of squalene within the fungal organism, leading to its death and thus resolving or reducing symptoms of various fungal infections like athlete's foot and ringworm.
Compared to itraconazole, which affects multiple steps in the biosynthesis of ergosterol (a key component of the fungal cell membrane), terbinafine specifically targets one step making it more potent and focused. Furthermore, terbinafine tends to have fewer side effects compared to itraconazole - particularly less impact on liver function - therefore may be preferred when a patient has pre-existing liver conditions. However, both medications should only be used under medical supervision due to their potential for serious side effects.
How effective are both Itraconazole and Terbinafine?
Both itraconazole and terbinafine have proven to be successful in treating fungal infections, particularly those affecting the nails (onychomycosis) and skin. They were approved by the FDA in the late 1980s and early 1990s respectively, yet they work differently to inhibit fungus growth. A double-blind clinical trial conducted in 2002 showed that both antifungals were equally effective at managing onychomycosis symptoms; however, some differences emerged when considering safety profiles and side effects.
A review of studies involving itraconazole from 2004 found that it is highly effective against a wide range of fungi causing skin and nail infections starting from the first week of treatment. Its broad-spectrum activity makes it a widely-prescribed antifungal worldwide. However, optimal efficacy usually requires pulse dosing over several months for nail infections due to slow nail growth rates. Itraconazole can also interact with numerous other medications which may limit its use in patients taking certain drugs.
On the other hand, a more recent meta-analysis carried out in 2016 indicated that terbinafine was not only more effective than placebo but also had superior cure rates compared with other common antifungals including itraconazole for toenail onychomycosis. Terbinafine's mechanism of action directly inhibits fungal cell membrane synthesis making it an excellent choice as a first-line therapy option for many dermatophyte infections. Even though most research involves using terbinafine alone rather than alongside another drug like an SSRI (as seen with bupropion), there is robust data confirming its standalone effectiveness for fungal conditions.
Related trials for itraconazole and terbinafine
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Itraconazole typically prescribed?
Oral dosages of Itraconazole typically range from 200–400 mg/day, depending on the severity and type of fungal infection. Children may be started at lower doses based on weight and age. The course length can vary between a few weeks to several months, depending on response to treatment. Terbinafine is usually prescribed at 250 mg/day for adults with toenail or fingernail fungus infections, over a period of six weeks for fingernails and twelve weeks for toenails. Dosages in children are also adjusted according to body weight and age. In either case, it's important not to exceed the recommended dosage unless advised by your healthcare provider.
At what dose is Terbinafine typically prescribed?
Terbinafine treatment typically begins with a dosage of 250 mg/day. This dose is taken once a day, not requiring division or spacing throughout the day. The course duration can range from 2 to 12 weeks depending on the nature and severity of the fungal infection. It's important to complete the full prescribed course even if symptoms improve before completion, to ensure thorough elimination of the fungus and prevent recurrence. If there is no response after several weeks of treatment at 250 mg/day, your healthcare provider may reassess your condition and consider alternative treatments.
What are the most common side effects for Itraconazole?
Some of the most common side effects of Itraconazole and Terbinafine may include:
- Headache
- Dizziness or feeling faint
- Indigestion, nausea, vomiting or abdominal pain
- Diarrhea or constipation
- Rash, itching or hives on the skin
- Changes in taste sensation
- Fatigue (general weakness and tiredness)
- Anorexia (loss of appetite)
- Jaundice (yellowing of the skin and eyes due to liver disease)
Remember that serious side effects are rare but if you experience any unusual symptoms such as severe dizziness, fainting, fast/irregular heartbeat seek immediate medical attention.
Are there any potential serious side effects for Itraconazole?
While both itraconazole and terbinafine are antifungal medications, they can have different side effects. Some potential severe side effects of itraconazole include:
- Signs of a serious allergic reaction, such as hives, difficulty breathing or swallowing, swelling in the face or throat.
- Severe skin reactions like blistering and peeling rashes.
- Vision changes such as blurred vision or double vision; if these occur, stop taking the medication immediately and seek medical attention.
- Heart problems may develop causing fast or irregular heartbeats leading to feelings of faintness or dizziness.
- Itraconazole might also cause significant liver damage with symptoms including persistent nausea/vomiting, loss of appetite, severe stomach/abdominal pain, yellowing eyes/skin.
On the other hand some rare but serious side effects associated with Terbinafine could be:
- Changes in sense of taste or smell which could be permanent
- Depression including thoughts about suicide
- Serious skin reactions (Stevens Johnson Syndrome)
- Liver disease - upper stomach pain that worsens after eating accompanied by dark urine -Fever due to decrease neutrophils count
In case you experience any unusual symptoms when taking either drug consult your healthcare provider right away.
What are the most common side effects for Terbinafine?
When taking Terbinafine, patients may experience the following side effects:
- Changes in taste or loss of taste
- Nausea, upset stomach or mild abdominal pain
- Diarrhea
- Headache or dizziness
- Rash, itching or hives on the skin
- Fatigue and general malaise Uncommonly, more serious side effects like liver problems (yellowing skin/eyes, dark urine), changes in mood such as depression, unexplained persistent fatigue may occur. It's crucial to consult a healthcare provider if any these symptoms appear.
Are there any potential serious side effects for Terbinafine?
While Terbinafine is generally safe for use, in rare cases it can cause serious side effects. Be vigilant for signs of a severe allergic reaction such as hives, difficulty breathing or swallowing, swelling in your face or throat, and a rash with blistering and peeling skin. More uncommon side effects may include mood changes or confusion. Visual disturbances such as blurred vision could also occur while using this medication. Serious instances of irregular heartbeat have been reported but are very rare. Lastly, liver problems might surface; symptoms to look out for include fatigue, upper stomach pain, dark urine and jaundice (yellowing of the skin or eyes). If you experience any unusual symptoms that persist or worsen while taking terbinafine, consult your healthcare provider immediately.
Contraindications for Itraconazole and Terbinafine?
Both Itraconazole and Terbinafine, like most antifungal medications, may cause side effects in some individuals. If you notice any severe reactions such as difficulty breathing, swelling of the face or throat, nausea, vomiting or abdominal pain after taking these medications, please seek immediate medical help.
Neither Itraconazole nor Terbinafine should be taken if you are using certain drugs for heart conditions since they can lead to potentially dangerous drug interactions. Always inform your healthcare professional about all the medications you're currently taking; this includes prescription drugs, over-the-counter medicines as well as herbal supplements.
Itraconazole is known to interact with a significant number of other drugs while terbinafine has fewer reported interactions but still requires caution especially with antidepressants and beta-blockers. Therefore it’s important to discuss your full medication list with your doctor before starting treatment with either of these antifungals.
Additionally both these drugs require monitoring of liver function due to their potential hepatotoxicity so regular blood tests might be ordered by your physician during the course of therapy.
How much do Itraconazole and Terbinafine cost?
For the brand name versions of these drugs:
- The price of 30 capsules of Itraconazole (100 mg) averages around $430, which works out to $14–28/day, depending on your dose.
- The price of 30 tablets of Terbinafine (250 mg) is about $1500, working out to approximately $50/day.
Thus, if you are in the higher dosage range for Itraconazole (i.e., 200 mg/day or higher), then brand-name Terbinafine is more expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
For the generic versions of Itraconazole and Terbinafine, costs are significantly lower:
- Itraconazole (100 mg tablets) is available in packs from 15 up to 60 capsules and above with approximate costs ranging from $1.40 to $4 per day for dosages between 100 and 300mg/day.
- Generic terbinafine is available in packs starting at quantities as low as seven tablets going up to about one hundred with prices ranging from roughly $.70 cents per day for lower doses up to nearly two dollars a day at higher doses.
Popularity of Itraconazole and Terbinafine
Itraconazole, available under the brand name Sporanox among others, is a broad-spectrum antifungal medication used to treat a variety of fungal infections. In 2020, it was estimated that Itraconazole had been prescribed to about 3 million people in the US. Itraconazole accounted for just over 8% of antifungal drug prescriptions in the country.
On the other hand, Terbinafine, marketed as Lamisil and others, is primarily used to treat nail fungus and athlete’s foot. It was prescribed to approximately 5 million people in the USA in 2020. In terms of prescription volume within antifungals category, Terbinafine represents around 15%. The use of terbinafine has remained steady over recent years while itraconazole usage shows an increasing trend due its broader spectrum coverage.
Conclusion
Both itraconazole and terbinafine have proven efficacy in treating fungal infections, strongly demonstrated by numerous clinical studies and meta-analyses that show their effectiveness over placebo treatments. However, due to the differences in their mechanisms of action - with itraconazole inhibiting the synthesis of ergosterol (a key component of fungal cell membranes), while terbinafine specifically inhibits a fungus-specific enzyme necessary for cell membrane production - they are typically prescribed under different circumstances.
Itraconazole is often chosen as first-line treatment for certain types of systemic fungal infections whereas terbinafine would generally be considered for tinea or onychomycosis (fungal nail) infections.
Both drugs are available in generic form which can contribute to significant cost savings particularly for patients who must pay out-of-pocket. Both may require some time before noticeable improvements occur as clearing up fungal infections can take weeks or even months.
In terms of side effects, both medications are usually well-tolerated but carry potential risks; liver damage being one such risk associated with both drugs although this side effect is rare. Hence, patients should stay alert to signs such as nausea, fatigue, dark urine or jaundice and seek immediate medical attention if these symptoms develop.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- TÜZÜN, Y., KOTOGYAN, A., & OGUZ, O. (1992, October). Terbinafine: Efficacy And Safety In The Treatment Of Dermatophytosis. International Journal of Dermatology. Wiley.http://doi.org/10.1111/j.1365-4362.1992.tb01382.x
- Caputo, R. (2003, December). Itraconazole (Sporanox®) in superficial and systemic fungal infections. Expert Review of Anti-infective Therapy. Informa UK Limited.http://doi.org/10.1586/14787210.1.4.531
- RYDER, N. S. (1992, February). Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. British Journal of Dermatology. Oxford University Press (OUP).http://doi.org/10.1111/j.1365-2133.1992.tb00001.x
- Krishnan-Natesan, S. (2009, October 30). Terbinafine: a pharmacological and clinical review. Expert Opinion on Pharmacotherapy. Informa UK Limited.http://doi.org/10.1517/14656560903307462
- Carnio, L. R., Johnson Shaw, M. E., Schnur, J., & Casadesus, D. (2021, January). Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis. BMJ Case Reports. BMJ.http://doi.org/10.1136/bcr-2020-238930
- Gupta, Lynde, Lauzon, Mehlmauer, Braddock, Miller, … Shear. (1998, March). Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. British Journal of Dermatology. Oxford University Press (OUP).http://doi.org/10.1046/j.1365-2133.1998.02140.x
- Katz. (1999, November). Drug interactions of the newer oral antifungal agents. British Journal of Dermatology. Oxford University Press (OUP).http://doi.org/10.1046/j.1365-2133.1999.00011.x
- Bootman, J. L. (1998, May). Cost-effectiveness of two new treatments for onychomycosis: An analysis of two comparative clinical trials. Journal of the American Academy of Dermatology. Elsevier BV.http://doi.org/10.1016/s0190-9622(98)70488-8
- Sigurgeirsson, Billstein, Rantanen, Ruzicka, Di Fonzo, Vermeer, … Evans. (1999, November). L.I.ON. Study: efficacy and tolerability of continuous terbinafine (LamisilR) compared to intermittent itraconazole in the treatment of toenail onychomycosis. British Journal of Dermatology. Oxford University Press (OUP).http://doi.org/10.1046/j.1365-2133.1999.00008.x
- Krob, H. A., Fleischer, A. B., Jr., D'Agostino, R., Jr., & Feldman, S. R. (2003, July). Terbinafine is More Effective Than Itraconazole in Treating Toenail Onychomycosis: Results from a Meta-analysis of Randomized Controlled Trials. Journal of Cutaneous Medicine and Surgery. SAGE Publications.http://doi.org/10.1007/s10227-002-0139-9